Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anabela Cardoso

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Zookeys|July 14, 2016
High-throughput biodiversity analysis: Rapid assessment of species richness and ecological interactions of Chrysomelidae (Coleoptera) in the tropicsJesús Gómez-Zurita, Anabela Cardoso, Indiana Coronado, et al.
Arthritis Care & Research|July 4, 2020
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid ArthritisKaleb Michaud, Janet Pope, Mart van de Laar, et al.
ACR Open Rheumatology|December 16, 2021
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of BaricitinibJanet E Pope, Yvonne C Lee, Jeffrey R Curtis, et al.
Rheumatology and Therapy|August 7, 2019
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USAChristine Radawski, Mark C Genovese, Brett Hauber, et al.
The Lancet. Rheumatology|January 26, 2024
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysisMark C Genovese, Josef S Smolen, Tsutomu Takeuchi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2019
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid ArthritisPeter C Taylor, Michael E Weinblatt, Gerd R Burmester, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
The Journal of Allergy and Clinical Immunology|September 13, 2020
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19Jonathan T Sims, Venkatesh Krishnan, Ching-Yun Chang, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Zookeys|July 14, 2016
High-throughput biodiversity analysis: Rapid assessment of species richness and ecological interactions of Chrysomelidae (Coleoptera) in the tropicsJesús Gómez-Zurita, Anabela Cardoso, Indiana Coronado, et al.
Arthritis Care & Research|July 4, 2020
Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid ArthritisKaleb Michaud, Janet Pope, Mart van de Laar, et al.
ACR Open Rheumatology|December 16, 2021
Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of BaricitinibJanet E Pope, Yvonne C Lee, Jeffrey R Curtis, et al.
Rheumatology and Therapy|August 7, 2019
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USAChristine Radawski, Mark C Genovese, Brett Hauber, et al.
The Lancet. Rheumatology|January 26, 2024
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysisMark C Genovese, Josef S Smolen, Tsutomu Takeuchi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 22, 2019
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid ArthritisPeter C Taylor, Michael E Weinblatt, Gerd R Burmester, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 28, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical TrialJoseph F Merola, Philip Mease, Alan Kivitz, et al.
RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
The Journal of Allergy and Clinical Immunology|September 13, 2020
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19Jonathan T Sims, Venkatesh Krishnan, Ching-Yun Chang, et al.
JAMA Dermatology|May 15, 2026
Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical TrialMark Lebwohl, Andrew Blauvelt, Cynthia E Kartman, et al.
Pageof 3